EJ 인간 방광암 세포에서 bufalin 의 TRAIL 저항성 극복 효과 = The Effect of overcoming the TRAIL resistance through bufalin in EJ human bladder cancer cell

다국어 초록 (Multilingual Abstract)

Objectives : Bufalin is one of the bioactive component of 'Sum Su (蟾酥)', which is obtained from the skin and parotid venom gland of toad. Bufalin has been known to possess the inhibitory effects on cell proliferation and inducing apoptosis in various cancer cells. The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has concerned, because it can selectively induce apoptotic cell death in many types of malignant cells, while it is relatively non-toxic to normal cells. Here, we investigated whether bufalin can trigger TRAIL-induced apoptotic cell death in EJ human bladder cancer cells. Methods : Effects on the cell viability and apoptotic activity were quantified using MTT assay and flow cytometry analysis, respectively. To investigate the morphological change of nucleus, DAPI staining was performed. Protein expressions were measured by immunoblotting. Results : A combined treatment with bufalin (10 nM) and TRAIL (50 ng/ml) significantly promoted TRAIL-mediated growth inhibition and apoptosis in EJ cells. The apoptotic effects were associated with the up-regulation of death receptor proteins, and the down-regulation of cFLIP and XIAP. Moreover, our data showed that bufalin and TRAIL combination activated caspases and subsequently increased degradation of poly(ADP-ribose) polymerase. Conclusions : Taken altogether, the nontoxic doses of bufalin sensitized TRAIL-mediated apoptosis in EJ cells. Therefore, bufalin might be an effective therapeutic strategy for the safe treatment of TRAIL-resistant bladder cancers.

참고문헌 (Reference)

1 심선진, "진행성 방광암의 항암화학요법" 대한내과학회 89 (89): 515-521, 2015

2 박철, "사간탕 처리에 의한 AGS 인체 위암세포의 caspase 활성 의존적 apoptosis 유발" 한국생명과학회 25 (25): 1384-1392, 2015

3 "http://www.koreantk.com/"

4 Safa AR., "c-FLIP, a master anti-apoptotic regulator" 34 (34): 176-184, 2012

5 LeBlanc H, "Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax" 8 (8): 274-281, 2002

6 Chen Z, "Triptolide sensitizes pancreatic cancer cells to TRAILinduced activation of the death receptor pathway" 348 (348): 156-166, 2014

7 Trivedi R, "Trailing TRAIL Resistance:Novel Targets for TRAIL Sensitization in Cancer Cells" 5 : 69-, 2015

8 Ewald F, "The role of c-FLIP splice variants in urothelial tumours" 2 : e245-, 2011

9 Ploeg M, "The present and future burden of urinary bladder cancer in the world" 27 (27): 289-293, 2009

10 Lim B, "Targeting TRAIL in the treatment of cancer: new developments" 19 (19): 1171-1185, 2015

11 Dai X, "Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy" 240 (240): 760-773, 2015

12 Szliszka E, "TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells" 47 (47): 579-585, 2009

13 Thorburn A, "TRAIL receptortargeted therapeutics: resistance mechanisms and strategies to avoid them" 11 (11): 17-24, 2008

14 Wang S, "TRAIL and apoptosis induction by TNF-family death receptors" 22 (22): 8628-8633, 2003

15 Ahmed SM, "Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells" 33 (33): 566-572, 2015

16 Yin XM., "Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways" 10 (10): 161-167, 2010

17 Kelley RF, "Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor- related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5than DR4 to apoptosis signaling" 280 (280): 2205-2212, 2005

18 Kim JH, "Quercetin sensitizes pancreatic cancer cells to TRAILinduced apoptosis through JNK-mediated cFLIP turnover" 78 : 327-334, 2016

19 White-Gilbertson SJ, "Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating antiapoptotic proteins" 182 (182): 1178-1185, 2009

20 Shalini S, "Old, new and emerging functions of caspases" 22 (22): 526-539, 2015

21 Jin CY, "Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells" 55 (55): 300-309, 2011

22 Li Y, "Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis" 79 (79): 968.e7-968.e15, 2012

23 Shuzhen C, "Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAILinduced apoptosis" 9 : 23-, 2010

24 Duriez PJ, "Cleavage of poly(ADP-ribose)polymerase: a sensitive parameter to study cell death" 75 (75): 337-349, 1997

25 Shamseddine A, "Cancer trends in Lebanon: a review of incidence rates for the period of 2003-2008 and projections until 2018" 12 (12): 4-, 2014

26 Yan S, "Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells" 25 (25): 683-689, 2014

27 Guancial EA, "Bladder cancer in the elderly patient: challenges and solutions" 10 : 939-949, 2015

28 Qi F, "Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor" 11 (11): 342-349, 2011

29 Yin PH, "Anti-tumor activity and apoptosisregulation mechanisms of bufalin in various cancers: new hope for cancer patients" 13 (13): 5339-5343, 2012